- Home
- PRFX vs SNPX Comparison
PRFX vs SNPX Comparison
Compare PRFX & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- SNPX
- Stock Information
- Founded
- PRFX 2007
- SNPX 2012
- Country
- PRFX Israel
- SNPX United States
- Employees
- PRFX N/A
- SNPX N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- PRFX Health Care
- SNPX Health Care
- Exchange
- PRFX Nasdaq
- SNPX Nasdaq
- Market Cap
- PRFX 3.8M
- SNPX 3.1M
- IPO Year
- PRFX 2020
- SNPX N/A
- Fundamental
- Price
- PRFX $2.32
- SNPX $2.30
- Analyst Decision
- PRFX Hold
- SNPX Strong Buy
- Analyst Count
- PRFX 1
- SNPX 1
- Target Price
- PRFX N/A
- SNPX $14.00
- AVG Volume (30 Days)
- PRFX 3.8M
- SNPX 11.5K
- Earning Date
- PRFX 05-14-2025
- SNPX 05-14-2025
- Dividend Yield
- PRFX N/A
- SNPX N/A
- EPS Growth
- PRFX N/A
- SNPX N/A
- EPS
- PRFX N/A
- SNPX N/A
- Revenue
- PRFX N/A
- SNPX N/A
- Revenue This Year
- PRFX N/A
- SNPX N/A
- Revenue Next Year
- PRFX N/A
- SNPX N/A
- P/E Ratio
- PRFX N/A
- SNPX N/A
- Revenue Growth
- PRFX N/A
- SNPX N/A
- 52 Week Low
- PRFX $0.43
- SNPX $1.84
- 52 Week High
- PRFX $16.63
- SNPX $5.38
- Technical
- Relative Strength Index (RSI)
- PRFX 51.08
- SNPX 48.08
- Support Level
- PRFX $1.92
- SNPX $2.05
- Resistance Level
- PRFX $2.37
- SNPX $2.21
- Average True Range (ATR)
- PRFX 0.27
- SNPX 0.19
- MACD
- PRFX 0.07
- SNPX 0.03
- Stochastic Oscillator
- PRFX 35.36
- SNPX 75.31
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.